Apogee Therapeutics
APGE
APGE was delisted on the 2nd of September, 2026.
288 hedge funds and large institutions have $8.93B invested in Apogee Therapeutics in 2026 Q2 according to their latest regulatory filings, with 115 funds opening new positions, 85 increasing their positions, 66 reducing their positions, and 47 closing their positions.
145% more first-time investments, than exits
New positions opened: 115 | Existing positions closed: 47
120% more funds holding in top 10
Funds holding in top 10: 10 → 22 (+12)
29% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 66
29% more funds holding
Funds holding: 224 → 288 (+64)
6.57% less ownership
Funds ownership: 115.72% → 109.15% (-6.6%)
25% less capital inflows, than outflows
Capital inflows: $2.39B | Capital outflows: $3.17B
77% less call options, than puts
Call options by funds: $37.3M | Put options by funds: $162M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HBK Investments
Dallas,
Texas
|
+$257M |
| 2 |
Glazer Capital LLC
New York
|
+$148M |
| 3 |
Pentwater Capital Management
Naples,
Florida
|
+$128M |
| 4 |
BlackRock
New York
|
+$128M |
| 5 |
Millennium Management
New York
|
+$126M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$859M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$610M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$343M |
| 4 |
RTW Investments
New York
|
-$234M |
| 5 |
Vestal Point Capital
New York
|
-$92.6M |
APGE Hedge Fund Activity: Q2 2026 in Review
288 of the 8,362 institutional investors tracked by Wall St. Rank reported a position in Apogee Therapeutics (APGE) for Q2 2026, worth a combined $8.93B — up 34% from $6.64B a quarter earlier.
Buyers outnumbered sellers: 115 funds opened new APGE positions and 47 closed out — a net gain of 68 holders — while 85 added to existing stakes and 66 trimmed.
The largest buyer was HBK Investments, opening a new position worth an estimated $257M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $859M.
- 288 institutional investors held Apogee Therapeutics (APGE) as of Q2 2026, up from 224 in Q1 2026.
- Funds reported $8.93B of Apogee Therapeutics stock for Q2 2026, up 34% quarter-over-quarter.
- 115 funds opened new Apogee Therapeutics positions in Q2 2026 and 47 closed out, a net change of +68 holders.
- The largest Apogee Therapeutics buyer in Q2 2026 was HBK Investments, an estimated $257M added.
- The largest Apogee Therapeutics seller in Q2 2026 was T. Rowe Price Investment Management, an estimated $859M sold.
Based on aggregated 13F filings for Q2 2026.